Views of Wall Street’s Leading Experts on Denali Therapeutics Inc.

Denali Therapeutics Inc. (NASDAQ: DNLI) stock fell -5.35% on Monday to $22.29 against a previous-day closing price of $23.55. With 0.78 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.66 million shares. The 52-week range on DNLI shows that it touched its highest point at $34.78 and its lowest point at $21.74 during that stretch. It currently has a 1-year price target of $55.60. Beta for the stock currently stands at 1.26.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of DNLI was down-trending over the past week, with a drop of -6.85%, but this was down by -2.62% over a month. Three-month performance dropped to -28.19% while six-month performance fell -4.46%. The stock lost -28.30% in the past year, while it has lost -19.85% so far this year. A look at the trailing 12-month EPS for DNLI yields -1.08 with Next year EPS estimates of -3.31. For the next quarter, that number is -0.82. This implies an EPS growth rate of -8.60% for this year and -175.80% for next year.

Float and Shares Shorts:

At present, 137.05 million DNLI shares are outstanding with a float of 117.24 million shares on hand for trading. On Aug 30, 2023, short shares totaled 9.09 million, which was 6.62% higher than short shares on Jul 30, 2023. In addition to Dr. Ryan J. Watts Ph.D. as the firm’s Co-Founder, Pres, CEO & Director, Dr. Alexander O. Schuth M.D. serves as its Co-Founder, CFO, COO & Sec.

Institutional Ownership:

Through their ownership of 80.44% of DNLI’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 46.26% of DNLI, in contrast to 44.22% held by mutual funds. Shares owned by individuals account for 30.60%. As the largest shareholder in DNLI with 10.80% of the stake, Baillie Gifford & Co. holds 14,843,770 shares worth 14,843,770. A second-largest stockholder of DNLI, The Vanguard Group, Inc., holds 9,919,991 shares, controlling over 7.22% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in DNLI, holding 8,220,387 shares or 5.98% stake. With a 4.75% stake in DNLI, the Scottish Mortgage Investment Trus is the largest stakeholder. A total of 6,532,566 shares are owned by the mutual fund manager. The Vanguard Health Care Fund, which owns about 3.58% of DNLI stock, is the second-largest Mutual Fund holder. It holds 4,920,721 shares valued at 113.62 million. Vanguard US Growth Fund holds 2.85% of the stake in DNLI, owning 3,920,479 shares worth 90.52 million.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, DNLI reported revenue of $52.48M and operating income of -$61.42M. The EBITDA in the recently reported quarter was -$59.34M and diluted EPS was -$0.48.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for DNLI since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With DNLI analysts setting a high price target of $105.00 and a low target of $26.00, the average target price over the next 12 months is $54.57. Based on these targets, DNLI could surge 371.06% to reach the target high and rise by 16.64% to reach the target low. Reaching the average price target will result in a growth of 144.82% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.

Summary of Insider Activity:

Insiders traded DNLI stock several times over the past three months with 2 Buys and 14 Sells. In these transactions, 12,526 shares were bought while 44,682 shares were sold. The number of buy transactions has increased to 26 while that of sell transactions has risen to 50 over the past year. The total number of shares bought during that period was 419,166 while 316,525 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *